ReviewWorld journal of diabetes2018
Treatment approach to type 2 diabetes: Past, present and future.
Review in World journal of diabetes, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence of type 2 diabetes in psychiatric disorders: an umbrella review with meta-analysis of 245 observational studies from 32 systematic reviews.Diabetologia · 2022Pooled it
- Differential Effects of Oral Antidiabetic Drugs on Skeletal Muscle Mass and Hemoglobin Levels in Adults with Type 2 Diabetes Mellitus: A Prospective Real-World Cohort Study.Journal of clinical medicine · 2026Article
- Luteolin mitigates hippocampal damage in a rat model of streptozotocin-induced diabetes.Biomolecules & biomedicine · 2025Article
- Dual effects ofNarra J · 2025Article
- The rise of weekly insulins: addressing the challenges of type 2 diabetes care in Brazil.Diabetology & metabolic syndrome · 2025Review
- Genetic Insights Into Type 2 Diabetes Mellitus Susceptibility: A Case-Control Study of theGenetics research · 2025Article
- In-patient expenditure between 2011 and 2021 for patients with type 2 diabetes mellitus: a hospital-based multicenter retrospective study in southwest China.Frontiers in public health · 2025Article
- Proposing a New Frontier in Diabetes Treatment: The Integration of Biotechnology and Artificial Intelligence.Journal of diabetes science and technology · 2024Article
- The Antidiabetic Potential of Probiotics: A Review.Nutrients · 2024Review
- A meta-analysis of the incidence of acne vulgaris in patients treated with GLP-1 agonists.International journal of women's dermatology · 2024Article
- Environmental endocrine disruptor-induced mitochondrial dysfunction: a potential mechanism underlying diabetes and its complications.Frontiers in endocrinology · 2024Review
- Predicting the diabetic foot in the population of type 2 diabetes mellitus from tongue images and clinical information using multi-modal deep learning.Frontiers in physiology · 2024Article
- Association of Monocyte-to-HDL Cholesterol Ratio with Endothelial Dysfunction in Patients with Type 2 Diabetes.Journal of diabetes research · 2024Article
- Bromocriptine and Colesevelam Hydrochloride: Novel Therapies for Type II Diabetes Mellitus.Cureus · 2023Review
- Sodium Glucose Transporter-2 Inhibitors (SGLT2Is)-TLRs Axis Modulates Diabetes.Cell biochemistry and biophysics · 2023Review
- Quantum Mechanical Prediction of Dissociation Constants for Thiazol-2-imine Derivatives.Journal of chemical information and modeling · 2023Article
- The Influence of Gut Microbial Species on Diabetes Mellitus.International journal of molecular sciences · 2023Review
- Essential Oils: Recent Advances on Their Dual Role as Food Preservatives and Nutraceuticals against the Metabolic Syndrome.Foods (Basel, Switzerland) · 2023Review
- Survival of Myocardial Infarction Patients with Diabetes Mellitus at the Invasive Era (Results from the Városmajor Myocardial Infarction Registry).Journal of clinical medicine · 2023Article
- Single nucleotide variations in the development of diabetic foot ulcer: A narrative review.World journal of diabetes · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 diabetes mellitus (DM) is a lifelong metabolic disease, characterized by hyperglycaemia which gradually leads to the development and progression of vascular complications. It is recognized as a global burden disease, with substantial consequences on human health (fatality) as well as on health-care system costs. This review focuses on the topic of historical discovery and understanding the complexity of the disease in the field of pathophysiology, as well as development of the pharmacotherapy beyond insulin. The complex interplay of insulin secretion and insulin resistance developed from previously known "ominous triumvirate" to "ominous octet" indicate the implication of multiple organs in glucose metabolism. The pharmacological approach has progressed from biguanides to a wide spectrum of medications that seem to provide a beneficial effect on the cardiovascular system. Despite this, we are still not achieving the target treatment goals. Thus, the future should bring novel antidiabetic drug classes capable of acting on several levels simultaneously. In conclusion, given the raising burden of type 2 DM, the best present strategy that could contribute the most to the reduction of morbidity and mortality should be focused on primary prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.